GlobeNewswire·May 27, 2026, 2:30 AM ET

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

ALGS

Aligos Therapeutics presented 10 positive data updates at the EASL Congress 2026 in Barcelona regarding its liver and viral disease programs.
Long-term follow-up data from a Phase 1 study of pevifoscorvir sodium suggests a reduction in the cccDNA reservoir in HBeAg+ participants with chronic HBV infection.
40% of HBeAg+ participants treated with pevifoscorvir sodium for 48 weeks achieved HBsAg levels <3,000 IU/mL, potentially qualifying them for ASO treatment.
Among 10 subjects who completed 96 weeks of pevifoscorvir sodium monotherapy followed by ≥24 weeks of NA monotherapy, 44% maintained HBV DNA below the lower limit of quantification.
Viral biomarkers including HBV antigens and HBV RNA remained reduced during the NA-only follow-up period, indicating pevifoscorvir sodium may reduce the cccDNA reservoir via its secondary CAM-E mechanism.
Preclinical data showed ALG-001075, the active parent of pevifoscorvir sodium, caused profound suppression of HBeAg, HBsAg, and HBV RNAs with durable effects after treatment withdrawal.
An analog of the ASO ALG-170675 demonstrated additive to synergistic antiviral effects when combined with ALG-001075 in vitro and in vivo.
New preclinical data on the hepatitis delta virus (HDV) program highlighted novel approaches to target HDV replication.
Data on ALG-055009, a THR-β agonist for MASH, showed synergistic fat mass loss in diet-induced obese mice when combined with incretin receptor agonists.
The company indicated pevifoscorvir sodium could potentially replace nucleos(t)ide analogs as the standard of care for chronic HBV infection.